Replies to post #140310 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

Classic problem solving tree shaping up here.

So with the goal of the exercise is to increase the homogeneity of the study population and avoids the noise

The obvious contradiction here. How to increase mix w/o compromising/losing the path to a simple solution? Eventually, we will get to understand how to deal w/this. Or not. A2-73 will probably not always be a one size fits all solution, depending on the criteria for acceptance. I think that is where he is going here.

No mention of the gut microbiome

Agree w/this point and think we all intuit that (at some point on the discovery path) unique DNA, what we eat and much more are certain to be factors in efficacy of any A2-73 treatment. That is where CNS AI precision medicine will have a custom bio-CNS-treatment for every patient.

The good news is, it is becoming more obvious every day that this is finally the right path to CNS wellness. We might ask, how long before AVXL will be snatched by others w/big money who will finish the job. That, and not when do trials start, is our question. Will that happen before/after the big AD paper delivery? Actually, A2-73 trials should be all conducted on the dunes at Kitty Hawk. This is CNS history in the making.

[F1ash]

I understood why he might have been unable to answer the question about the results on the genomic testing results, since they will be presented at an upcoming conference.

What I do not understand is why Anavex is reluctant to divulge the budget for the planned trials. I can come up with a few different guesses about the reasoning that would not be popular. If they are planning to start in the next ~140 days, does it seem reasonable that they don’t have cost estimates yet?


Caroline Palomeque

“Okay, great. And then just wondering if you could give any guidance on what you expect the cost of some of the trials will be, I'm just not sure if that was guided to before, just all the programs in Phase 2?”



Christopher Missling

“The cost of the programs has not been explicitly disclosed. “




“We want to start as soon as reasonably possible and we don't need to wait until we disclose the data of the genomic outcome. So we'll try to submit the IND as soon as later and we said publicly today that we would do it within the 2018 first half of the year.”




Anavex's (AVXL) CEO Christopher Missling on Q1 2018 Results - Earnings Call Transcript $AVXL